{{Drugbox
| IUPAC_name = 7-chloro-''N''-[(2''S'')-1-[2-(cyclopropylsulfonylamino)ethylamino]-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide
| image = ADSB-FUB-187_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1185283-97-9
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 44186812
| ChemSpiderID      = 
| smiles            = CC(C)(C)[C@@H](C(=O)NCCNS(=O)(=O)C1CC1)NC(=O)C2=NN(C3=C2C=CC=C3Cl)CC4=CC=C(C=C4)F
| StdInChI          = 1S/C26H31ClFN5O4S/c1-26(2,3)23(25(35)29-13-14-30-38(36,37)18-11-12-18)31-24(34)21-19-5-4-6-20(27)22(19)33(32-21)15-16-7-9-17(28)10-8-16/h4-10,18,23,30H,11-15H2,1-3H3,(H,29,35)(H,31,34)/t23-/m1/s1
| StdInChIKey       = UANJTRHQSBHCID-HSZRJFAPSA-N

<!--Chemical data-->
| C=26 | H=31 | N=5 | O=4 | F=1 | S=1 | Cl=1 
| molecular_weight = 564.07 g/mol
}}

'''ADSB-FUB-187''' is an [[indazole]]-based [[synthetic cannabinoid]]. It is a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] with a [[binding affinity]] of ''K''<sub>i</sub>&nbsp;=&nbsp;0.09&nbsp;nM and an [[EC50|EC<sub>50</sub>]] of 1.09&nbsp;nM. It was originally developed by [[Pfizer]] in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of ''K''<sub>i</sub>, it is not the most potent compound at producing a CB<sub>1</sub> mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC<sub>50</sub> values.<ref>{{cite journal | url=http://www.google.com/patents/WO2009106982A1 | title=Patent WO/2009/106982 - Indazole derivatives}}</ref>

==Legality==
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market [[synthetic cannabis]] products.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | publisher=Folkhälsomyndigheten | title=Cannabinoider föreslås bli klassade som hälsofarlig vara  | language=Swedish | accessdate=8 July 2015}}</ref>

==See also==
* [[AB-FUBINACA]]
* [[ADB-FUBINACA]]


==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Indazoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazolecarboxamides]]

{{cannabinoid-stub}}